RedHawk Holdings Corp. (company) announced that RedHawk Pharma UK Ltd. (RedHawk Pharma), a wholly-owned subsidiary of RedHawk, has agreed in principle to enter into definitive marketing and operational joint venture agreements (joint venture agreements) with ICE Pharma Group (“IPG”). When the EU License Acquisition is complete, RedHawk Pharma will own approximately 120 generic EU licensing assets and have approximately $15,000,000 of tax loss carryforwards available to offset future profits in the United Kingdom. The company announced that this new alliance with IPG will better position RedHawk Pharma to successfully integrate EcoGen and the EU License Acquisition, manage the anticipated growth of this business unit, and enhance the probability of successfully completing other organic and strategic business opportunities in the future.